Employers are projecting the healthcare value development to extend by a median of 9% for 2026, and seven.6% after they make plan design modifications, in line with a Tuesday survey from the Enterprise Group on Well being, an employer advocacy group.
“That is the best single-year forecast in additional than a decade,” stated Ellen Kelsay, president and CEO of the Enterprise Group on Well being, throughout a press briefing. “The compounding impact of excessive healthcare development will increase signifies that by 2026, healthcare prices [are] projected to be 62% larger than they have been in 2017.”
For the second 12 months in a row, precise healthcare prices exceeded the forecasted value for employers. In 2024, employers anticipated a 7.1% enhance in healthcare prices, and truly skilled a 7.5% enhance. In 2023, employers anticipated a 6.6% enhance in prices, and skilled a 6.8% enhance. As well as, two-thirds of employers say that rising prices are affecting their capacity to offer international advantages.
The Annual Employer Well being Care Technique Survey obtained responses from 121 employers throughout a wide range of industries. These employers collectively cowl 11.6 million folks globally.
Further findings from the survey embody:
1. Prescription drug prices are a serious contributor to healthcare prices. In 2024, pharmacy accounted for a median of 24% of general healthcare spend, in comparison with 21% in 2021. And GLP-1s are partly accountable, with 72% of respondents saying that they drive prices to a “very nice extent” or a “nice extent.” One other 61% stated the identical about high-cost therapies.
2. Nearly all employers cowl GLP-1s for diabetes, whereas 73% cowl them for weight problems. And about 79% of employers stated they’re seeing elevated utilization of weight problems therapies. On the subject of masking GLP-1s for weight problems, the commonest utilization administration techniques are prior authorization, requiring participation in a weight administration program and assembly a sure physique mass index threshold.
3. When requested what circumstances are driving prices, 88% stated most cancers, 71% stated musculoskeletal circumstances and 35% cited cardiovascular circumstances. That is the fourth 12 months in a row during which most cancers is the highest situation contributing to value. To handle most cancers prices, many employers are increasing protection of most cancers screenings, together with for colon most cancers, breast most cancers and pores and skin most cancers. About half of the respondents additionally stated that they may supply entry to facilities of excellence for most cancers in 2026.
4. To cut back healthcare prices, employers’ prime methods embody leveraging the request for proposal course of to get higher pricing from incumbents or new distributors, eliminating lower-utilized packages, changing underperforming distributors, and limiting protection for GLP-1s.
5. About 17% of employers have adopted a non-traditional or various well being plan, whereas 7% are including it in 2026 and 36% are contemplating it for 2027 or 2028. As well as, 16% are utilizing a clear pharmacy profit supervisor, whereas 11% are including one in 2026 and 43% are contemplating it in 2027 or 2028. Nevertheless, switching to a brand new pharmacy pricing or contracting mannequin doesn’t come with out its challenges, together with “issue of calculating the monetary impression of the conversion and no urge for food for member disruption,” the report said.
6. Employers are additionally being attentive to a number of coverage initiatives. About 85% of respondents need the federal government to guard the tax therapy of employer well being protection, 81% need the federal government to guard ERISA preemption and 62% need the federal government to handle prescription drug pricing. As well as, 66% of employers stated they’re involved or very involved that modifications to authorities packages (corresponding to Medicare and Medicaid) will hurt employer-sponsored protection.
This wasn’t shocking because it aligns with “long-held employer beliefs that efforts to cut back prices for packages like Medicare and Medicaid will usually end in value shifting to employer-sponsored plans,” stated Brenna Shebel, vice chairman of the Enterprise Group on Well being, through the press briefing.
Picture: PM Photos, Getty Photos
